A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Inclusion Criteria:

• Patients who have been diagnosed with NMIBC in the previous 2 years, and are attendingthe urology clinic for standard of care/routine monitoring cystoscopy
• Patients 22 years of age or older
• Patients who, in the opinion of the Investigator, are suitable for standard urologicalinvestigations as part of normal clinical practice
• Patients who are, in the opinion of the Investigator, able to understand the purposeof the study and provide a full void urine specimen
• Patients who are able to give voluntary, written informed consent to participate inthis study

Exclusion Criteria:

• Patients with known active (symptomatic) calculi within the urino-genitary system
• Patients who provide less than 10mL of full void urine
• Patients undergoing active treatment for interstitial cystitis
• Patients currently undergoing systemic chemotherapy or systemic immunotherapy orradiotherapy. Intravesical chemotherapy or immunotherapy (BCG) is allowed
• Patients who have previously been diagnosed with renal cancer, prostate cancer, MuscleInvasive Bladder cancer, an upper tract tumour, or CiS in the prostatic urethra
• Patients who have had urological instrumentation to the urinary tract within 14 daysprior to the test
• Male patients undergoing active treatment for prostatitis